George B. Pasikhov

George B. Pasikhov

Auto-generated profile, based on publicly available information

George B. Pasikhov

National Research Center – Institute of Immunology of the Federal Medical-Biological Agency, Moscow

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2024 in Immunologiya
Verified
Journal Article
Open access
ISIgor Shilovskiy
Igor Shilovskiy
ETE.D. Timotievich
E.D. Timotievich
MKM.M. Kaganova
M.M. Kaganova
GPG.B. Pasikhov
G.B. Pasikhov
ATA.D. Tahanovich
A.D. Tahanovich
MKM.R. Khaitov
M.R. Khaitov
Роль триады цитокинов, продуцируемых респираторным эпителием, в патогенезе аллергического ринита

1 January 2023 in Immunologiya
Verified
Journal Article
Open access
EKE.V. Kovaleva
E.V. Kovaleva
SRS.P. Rybalkin
S.P. Rybalkin
VSV.A. Shangaraeva
V.A. Shangaraeva
YIYu.V. Ivanova
Yu.V. Ivanova
GPG.B. Pasikhov
G.B. Pasikhov
MKM.R. Khaitov
M.R. Khaitov
Изучение репродуктивной токсичности рекомбинантной аллерговакцины для лечения аллергии на пыльцу березы и перекрестные аллергены

1 January 2026 in Immunologiya
Verified
Journal Article
Open access
GPG.B. Pasikhov
G.B. Pasikhov
ISIgor Shilovskiy
Igor Shilovskiy
MPM.V. Popova
M.V. Popova
PSP.A. Strueva
P.A. Strueva
Roman EsipovRoman Esipov
Roman Esipov
MKM.R. Khaitov
M.R. Khaitov
Комплексный анализ in silico потенциальных В-клеточных IgE-эпитопов мажорных аллергенов пыльцы амброзии Amb a 1 и Amb a 11

14 June 2024 in Biological Products. Prevention, Diagnosis, Treatment
Verified
Journal Article
Open access
PDF file
ISIgor Shilovskiy
Igor Shilovskiy
GPG. B. Pasikhov
G. B. Pasikhov
VSValery Smirnov
Valery Smirnov
IKIlya Kofiadi
Ilya Kofiadi
MPM. V. Popova
M. V. Popova
MKM. R. Khaitov
M. R. Khaitov
INTRODUCTION. Small interfering RNAs (siRNAs) are among the most promising types of therapeutic nucleic acids aiming at the inhibition of pathogenetically relevant gene expression through the RNA interference mechanism. However, the limited bioavailability and immunogenicity of siRNAs and imperfect delivery systems hinder the clinical potential and applicability of siRNA medicinal products.AIM. This study aimed to summarise recent advances in the development of siRNA medicinal products and the corresponding delivery systems, review clinical trial results, and outline future development prospects for these medicinal products.DISCUSSION. This article covers the molecular mechanisms underlying RNA interference, the considerations for siRNA development, and the techniques for effective siRNA delivery. The article dwells upon various systems for nucleic acid delivery to targeted cells. The most promising delivery systems are non-viral systems, including liposomes, exosomes, nanoparticles, polymers, cell-penetrating peptides, and GalNAc ligands. Their main advantages include their ease of complexation with nucleic acids, modification and functionalization potential, favourable safety profile, ability to cross biological barriers, and tropism to target tissues. The article summarises the information that has accumulated over the past few years in clinical trials of siRNA medicinal products for a range of conditions, including metabolic disorders, infections, and cancers, as well as hereditary, ophthalmic, renal, and hepatic diseases. Special attention is paid to siRNA medicinal products undergoing clinical trials (over 10 products) and approved for clinical use (6 products, including MIR 19, the first authorised Russian siRNA medicinal product).CONCLUSION. Ultimately, siRNA medicinal products are a promising tool for personalised medicine, exhibiting therapeutic potential for a wide range of pathological conditions. Further studies of siRNA medicinal products should aim at improving siRNA production technology to increase their bioavailability and half-life period. In addition, these studies should aim at enhancing delivery systems for these products to mitigate toxicity risks and maximise efficacy.

5 September 2025 in Allergy
Verified
Journal Article
Closed access
GPGeorge B. Pasikhov
George B. Pasikhov
ISIgor Shilovskiy
Igor Shilovskiy
ANAleksandr A. Nikolskii
Aleksandr A. Nikolskii
KYKirill V. Yumashev
Kirill V. Yumashev
MKMariya M. Kaganova
Mariya M. Kaganova
MKMusa R. Khaitov
Musa R. Khaitov

1 January 2024 in Immunologiya
Verified
Journal Article
Open access
ANA.A. Nikolskii
A.A. Nikolskii
ISIgor Shilovskiy
Igor Shilovskiy
Nina VorobjevaNina Vorobjeva
Nina Vorobjeva
KYK.V. Yumashev
K.V. Yumashev
GPG.B. Pasikhov
G.B. Pasikhov
MKM.R. Khaitov
M.R. Khaitov
Влияние интерлейкина-37 на процесс НЕТоза у нейтрофилов человека in vitro